Company Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors.
The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 26, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Zhengbin Yao |
Contact Details
Address: 18 Campus Boulevard, Suite 100 Newtown Square, Pennsylvania 19073 United States | |
| Phone | 628 277 4836 |
| Website | arrivent.com |
Stock Details
| Ticker Symbol | AVBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001868279 |
| CUSIP Number | 04272N102 |
| ISIN Number | US04272N1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President and Chief Executive Officer |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research and Development and Director |
| Robin LaChapelle M.A. | Co-Founder and Chief Operating Officer |
| Winston Kung M.B.A. | Chief Financial Officer and Treasurer |
| Yang Wang Ph.D. | Chief Technology Officer |
| James Paul Kastenmayer J.D., Ph.D. | General Counsel and Secretary |
| Meghna Chowdary | Senior Vice President of Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 3, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |